Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269122 · ClinicalTrials.gov registry record
A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
A clinical trial of Ornithine Transcarbamylase Deficiency, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT04269122 is a study of Ornithine Transcarbamylase Deficiency that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 120 participants, above the 37-participant average among 4 other Ornithine Transcarbamylase Deficiency trials with a reported enrollment target (224% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04269122, a study of Ornithine Transcarbamylase Deficiency, has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to characterize 24-hour plasma ammonia levels, characterize urea production rates in healthy normal subjects.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Texas
- PPD Phase 1 Unit - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2020-02-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04269122
The ClinicalTrials.gov registry entry for NCT04269122 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 37-participant average among 4 other Ornithine Transcarbamylase Deficiency trials with a reported enrollment target (224% higher). The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ornithine Transcarbamylase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT04269122 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04269122 about?
NCT04269122 is a clinical study titled "A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects". The objective of the study is to characterize 24-hour plasma ammonia levels, characterize urea production rates in healthy normal subjects.
What is the current status of trial NCT04269122?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2019-08-02. Estimated completion is 2020-02-20.
What conditions does trial NCT04269122 study?
This clinical trial studies the following conditions: Ornithine Transcarbamylase Deficiency.
What interventions are being tested in trial NCT04269122?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04269122?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04269122 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ornithine Transcarbamylase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liver Disease in Urea Cycle Disorders
RECRUITING
-
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
RECRUITING · Phase 1
-
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
RECRUITING · Phase 2
-
Hepatic Histopathology in Urea Cycle Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.